A strong pharma business: why Freedom recommends Johnson & Johnson shares
Stock Market News
20 октября 2026, 10:37
Freedom Broker analysts maintained their “Buy” recommendation on shares of Johnson & Johnson (JNJ), a manufacturer of pharmaceuticals and medical devices, with a target price of $280. Experts view the slowdown in the medical technology business as temporary and expect new drugs to continue supporting the company’s growth. The upside cited in the report is nearly 10%, while the current quote is $255.56.

About the company in brief
Johnson & Johnson operates in two main segments: Innovative Medicine covers pharmaceuticals, while MedTech includes medical devices and technologies. Freedom’s investment thesis is based primarily on the company’s positions in oncology, immunology, and neuroscience.
TREMFYA offsets the decline in STELARA sales
Freedom experts view the current segment slowdown as temporary and believe that Innovative Medicine’s strong competitive positions, especially in oncology, immunology, and neuroscience, will continue to support the company’s growth.
One of the key results of the third quarter was a 68.3% year-over-year increase in TREMFYA sales to $2.40 billion. It is a drug used to treat inflammatory diseases, including psoriasis, psoriatic arthritis, and inflammatory bowel disease. Its active ingredient, guselkumab, blocks a protein involved in the development of inflammation. For the first time, the increase fully offset the decline in STELARA sales in absolute terms: TREMFYA revenue rose by about $972 million, while STELARA’s fell by $854 million to $716 million.
TREMFYA sales have significantly exceeded Freedom’s forecast for a second consecutive quarter; the forecast had been $2.0 billion. Analysts revised their outlook for the drug and now expect its peak annual revenue could reach $13 billion.
Additional support came from the Neuroscience unit, which includes drugs for diseases of the nervous system and mental disorders. Its revenue rose 17.3% to $2.38 billion. CAPLYTA sales increased 66.1% to $398 million, and SPRAVATO sales rose 36.1% to $624 million. Experts consider these drugs key sources of Innovative Medicine growth in the medium term.
Revenue beat market expectations, profit came under pressure
For the third quarter of 2026, Johnson & Johnson revenue totaled $25.4 billion, up 5.9% year over year. The figure matched Freedom Broker’s forecast and exceeded the FactSet consensus of $25.28 billion. U.S. sales rose 9.1% to $15.0 billion, while international revenue increased 1.5% to $10.4 billion. Innovative Medicine increased revenue 7.7% to $16.8 billion, while MedTech rose 2.5% to $8.6 billion.
At the same time, higher expenses weighed on profit. Research and development costs increased 26.7% to $4.65 billion. Adjusted pre-tax profit fell 9.1% to $7.67 billion, and the corresponding margin declined from 35.2% to 30.2%.
Adjusted earnings per share were $2.59, down 7.5% year over year, but above the FactSet consensus of $2.54. This metric excludes certain items that affect reported earnings. Analysts attribute a significant portion of the margin pressure to the acquisition of Firefly Bio and investments in collaboration with Sail Biomedicines and do not carry the full effect into their long-term estimates.
Why MedTech weakness did not change the recommendation
The main source of the MedTech slowdown was international markets, where revenue was essentially unchanged. According to management, sales were affected by the reallocation of government budgets amid the conflict in the Middle East, austerity measures in Europe, and price competition in China.
Analysts view these factors as largely macroeconomic and geopolitical. In their assessment, the results do not indicate a structural deterioration in Johnson & Johnson’s competitive position.
A separate event will be the spin-off of the Orthopaedics business into an independent company. It accounts for about 10% of JNJ’s total revenue. Freedom Broker believes this will allow the company to focus resources on faster-growing areas of medical technology.
The company raised its full-year forecast
Johnson & Johnson raised its 2026 revenue forecast to $101.0–101.4 billion from $100.8–101.4 billion. Expectations for adjusted earnings per share were increased to $11.05–11.15 from $10.96–11.11. Analysts attribute the modest guidance raise to more restrained expectations for MedTech in the fourth quarter. Among the risks, they highlight tariff policy, intensifying competition, and a steeper-than-expected decline in drug sales after loss of exclusivity.
The oncology portfolio is becoming more diversified
Revenue from the oncology business rose 16.4% year over year. In addition to DARZALEX, growth is being driven by CARVYKTI, TECVAYLI, TALVEY, and the RYBREVANT/LAZCLUZE combination. In analysts’ view, this reduces the segment’s dependence on a single drug.
Earlier, Freedom experts noted strong results from a study of TALVEY in combination with DARZALEX FASPRO in patients with relapsed or refractory multiple myeloma. According to the data provided, the regimen reduced the risk of disease progression or death by 72% compared with standard treatment. Analysts consider expanding the use of new drugs at earlier stages of therapy one of the factors behind further growth of the oncology business.
This is not an individual investment recommendation.